Predicted to enable nucleic acid binding activity and zinc ion binding activity. Predicted to contribute to DNA-directed 5'-3' RNA polymerase activity. Predicted to be involved in maintenance of transcriptional fidelity during transcription elongation by RNA polymerase II; transcription initiation at RNA polymerase II promoter; and transcription-coupled nucleotide-excision repair. Predicted to be located in nucleoplasm. Predicted to be part of RNA polymerase II, core complex. Orthologous to human POLR2I (RNA polymerase II subunit I); PARTICIPATES IN RNA polymerase II transcription pathway; Huntington's disease pathway; purine metabolic pathway; INTERACTS WITH 2,2',4,4'-Tetrabromodiphenyl ether; 2,3,7,8-tetrachlorodibenzodioxine; 3-chloropropane-1,2-diol.
DNA-directed RNA polymerase II subunit RPB9; LOC103690054; LOC292778; polymerase (RNA) II (DNA directed) polypeptide I; polymerase (RNA) II (DNA directed) polypeptide I, 14.5kDa; polymerase (RNA) II subunit I
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of POLR2I mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of POLR2I mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of POLR2I mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of POLR2I mRNA